Biocad Biotechnology Company has signed an agreement with The Almazov National Medical Research Centre on conducting joint research in the field of treatment of cancer with the help of chimeric antigenic receptors (CAR-T). The head of Biocad Dmitry Morozov promised that the cost of creating an individual cellular immune drug for one patient will amount to 16 million rubles – half as cheap as imported analogues.
The director of the center Yevgeny Shlyakhto has signed the agreement on the side of The Almazov National Medical Research Centre, on the side of Biocad it has been the general director of the biotechnology company Dmitry Morozov. Deputy Minister of Health Sergey Kraievoy attended the signing ceremony on May 24 at the St. Petersburg International Economic Forum (SPIEF).
According to Dmitry Morozov, the cost of manufacturing of individual CAR-T products per patient will not exceed 16 million rubles, which is half as cheap as it is in foreign clinics. Within three years after the procedure, the patient will not need additional treatment, except for periodic doctor medical examination.
For reference, CAR-T-based therapy called Kymriah, which has been developed by the Swiss company Novartis, costs $ 475,000.
In March 2018, Biocad signed a joint project with the Ministry of Health of the Russian Federation on the construction of a cellular technology center for the treatment of cancer in St. Petersburg in which the company plans to invest $ 26 million in two years.
A similar document on oncotherapy research using CAR-T-cell technologies, the main competitor of Biocad , Russian pharmaceutical company "R-Farm" and Sechenov University have signed on the SPIEF.
© All rights reserved, 2015-2019